Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.

Following a successful appeal of a December 2025 CRL, the FDA concluded that Outlook Therapeutics' existing data provided substantial evidence, eliminating the need for new clinical trials.

A wearable ultrasound patch can provide continuous, real-time information about blood flow in the fetus and umbilical cord, according to a study published online May 26 in Nature Biotechnology. Geonho ...

Credit: Bayer. Two phase 3 trials supported the approval of gadoquatrane, a novel macrocyclic GBCA for imaging CNS and non-CNS pathologies. The novel macrocyclic contrast agent delivers high-quality ...

Phase 3 ISLEND-1 and ISLEND-2 trials met primary endpoints at week 48, showing a novel, once-weekly oral single-tablet regimen is noninferior to daily B/F/TAF or standard ART.

Findings showed navacaprant did not significantly improve MADRS total scores compared with placebo in either KOASTAL-2 (P =.813) or KOASTAL-3 (P =.480). Topline data were announced from two phase 3 ...

The group said the move was spurred by its commitment to evidence-based medicine amid a landscape of conflicting public health information.

Data show that orforglipron, a once-daily oral GLP-1 receptor agonist, drives significant, long-term weight reduction in women with obesity or overweight across all 3 stages of menopause: premenopause ...

Results showed ozekibart significantly reduced the risk of disease progression or death by 52% compared with placebo. The Food and Drug Administration (FDA) has accepted for review the Biologics ...

The FDA linked 12 severe kidney complications to alli between 2007 and 2023, resulting in 8 hospitalizations and 5 patients requiring dialysis. The Food and Drug Administration (FDA) has updated the ...

Three studies show benefits in adults inadequately controlled with diet and exercise, receiving metformin, using basal insulin ...